{"id":"ryanodex-and-standard-of-care","safety":{"commonSideEffects":[{"rate":null,"effect":"Muscle weakness"},{"rate":null,"effect":"Phlebitis at injection site"},{"rate":null,"effect":"Drowsiness"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL13829","moleculeType":"Small molecule","molecularWeight":"768.84"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dantrolene acts as a ryanodine receptor antagonist, preventing uncontrolled calcium efflux from intracellular stores in skeletal muscle. This mechanism is particularly effective in treating malignant hyperthermia, a pharmacogenetic crisis triggered by certain anesthetics and depolarizing muscle relaxants. By reducing intracellular calcium availability, dantrolene prevents the hypermetabolic cascade and muscle rigidity characteristic of malignant hyperthermia.","oneSentence":"Ryanodex is a dantrolene sodium formulation that blocks calcium release from the sarcoplasmic reticulum in skeletal muscle by inhibiting the ryanodine receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:58.935Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Malignant hyperthermia crisis (acute treatment)"},{"name":"Malignant hyperthermia susceptibility (prophylaxis)"}]},"trialDetails":[{"nctId":"NCT02513095","phase":"PHASE2","title":"Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)","status":"COMPLETED","sponsor":"Eagle Pharmaceuticals, Inc.","startDate":"2015-09","conditions":"Heat Stroke","enrollment":34},{"nctId":"NCT03600376","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS","status":"COMPLETED","sponsor":"Eagle Pharmaceuticals, Inc.","startDate":"2018-08-19","conditions":"Exertional Heat Stroke","enrollment":17},{"nctId":"NCT03189433","phase":"PHASE2","title":"Efficacy and Safety Study of Ryanodex as Adjuvant Treatment in Subjects With Psychostimulant Drug-Induced Toxicity (PDIT)","status":"TERMINATED","sponsor":"Eagle Pharmaceuticals, Inc.","startDate":"2017-08-12","conditions":"Drug Toxicity Psychotropic Agents Psychostimulants","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ryanodex and SOC"],"phase":"phase_3","status":"active","brandName":"Ryanodex and Standard of Care","genericName":"Ryanodex and Standard of Care","companyName":"Eagle Pharmaceuticals, Inc.","companyId":"eagle-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ryanodex is a dantrolene sodium formulation that blocks calcium release from the sarcoplasmic reticulum in skeletal muscle by inhibiting the ryanodine receptor. Used for Malignant hyperthermia crisis (acute treatment), Malignant hyperthermia susceptibility (prophylaxis).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}